Tolerability and efficacy of the trifunctional antibody removab^®(anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study

• Bois A du,
• Moiseenko V,
• Biakhov M,
• Eiermann W,
• Ströhlein M,
• Makhson A,
• Lichinitser M,
• Pfisterer J,
• Schmalfeldt B,
• Sommer H,
• Gorbounova V,
• Burges A,
• Wimberger P,
• Kimmig R

Affiliations

Bois A du

Moiseenko V

Biakhov M

Eiermann W

Ströhlein M

Makhson A

Lichinitser M

Pfisterer J

Schmalfeldt B

Sommer H

Gorbounova V

Burges A

Wimberger P

Kimmig R